The US Food & Drug Administration always emphasizes that it makes drug approval decisions based on a set of statutory standards that do not change.
There are not different rules for different diseases.
An advisory committee rejection of the proposed ALS therapy AMX0035 amounts to a vote in favor of US FDA’s approach to the review. It also amounts to an implicit rejection of the idea that ALS merits unique approaches given the devastating nature of the illness.

The US Food & Drug Administration always emphasizes that it makes drug approval decisions based on a set of statutory standards that do not change.
There are not different rules for different diseases.
A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.